Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Genzyme Molecular Oncology and Dana-Farber agreement for fusion cell technology

June 5, 1998

Vical reports initial results from gene-based immunotherapy for prostate cancer

June 4, 1998

FDA advisory committee recommends approval of Ontak for CTCL

June 3, 1998

European Commission clears rituximab for marketing in member countries

June 3, 1998

Idec receives patent protection for radioimmunotherapy

June 3, 1998

Antisoma and Imperial Cancer Research Technology announce collaboration

May 27, 1998

Glaxo Wellcome's 3622W94: phase I trial results presented at ASCO

May 26, 1998

Pivotal trials of Allovectin-7 begin in advanced metastatic melanoma

May 26, 1998

MDX-210 shows significant antitumor activity in prostate and kidney cancer patients

May 22, 1998

97% response rate for Rituxan + CHOP in small pilot trial in intermediate- or high-grade NHL

May 21, 1998

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...